Marla J Husnik1, Elizabeth R Brown, Mark Marzinke, Edward Livant, Thesla Palanee-Phillips, Craig W Hendrix, Flavia Matovu Kiweewa, Gonasagrie Nair, Lydia E Soto-Torres, Katie Schwartz, Sharon L Hillier, Jared M Baeten. 1. *Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA; †University of Washington, Seattle, WA; ‡Johns Hopkins University School of Medicine, Baltimore, MD; §Magee-Womens Research Institute & Foundation, University of Pittsburgh Medical Center, Pittsburgh, PA; ‖Wits Reproductive Health and HIV Institute, University of Witwatersrand, Hillbrow Health Precinct, Johannesburg, South Africa; ¶Makerere University-John Hopkins University Research Collaboration, Kampala, Uganda; #Center for AIDS Programme of Research in South Africa, Durban, South Africa; **Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health Rockville, MD; ††FHI 360, Durham, NC; and ‡‡Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA.
Abstract
BACKGROUND:Placebo-controlled HIV-1 prevention trials of pre-exposure prophylaxis (PrEP) have not generally used concurrent measurement of adherence because of the potential risk of unblinding. However, several pre-exposure prophylaxis trials for HIV-1 prevention among women failed to show effectiveness because of low product adherence. Evaluation of product adherence objectively during a study provides the opportunity for strengthening adherence activities at sites having low adherence. METHODS: During MTN-020/ASPIRE, a phase III, placebo-controlled trial of the dapivirine intravaginal ring, we implemented an adherence monitoring system. Monitoring began in quarter 1 (Q1) 2013 and continued through the conclusion of the trial. Blood plasma was collected quarterly and tested for dapivirine concentrations while maintaining blinding among study team members involved in participant management. Dapivirine concentrations >95 pg/mL, reflecting >8 hours of continuous use, were assessed as signaling product use. Study leadership monitored results on a monthly basis and provided feedback to site investigators. Experiences were shared across sites to motivate staff and counsel participants to strive toward higher adherence levels. RESULTS: An upward trend in adherence was observed (P < 0.0001); the proportion of samples from subjects in the active arm with dapivirine >95 pg/mL increased from 63% in Q1 2013 to 84% by Q1 2015. CONCLUSIONS: Ongoing drug level testing as a marker of adherence in MTN-020/ASPIRE demonstrates the feasibility of real-time adherence monitoring while maintaining study blinding at the level of participants, sites, and study leadership. This approach is novel for large-scale effectiveness studies for HIV-1 prevention.
RCT Entities:
BACKGROUND: Placebo-controlled HIV-1 prevention trials of pre-exposure prophylaxis (PrEP) have not generally used concurrent measurement of adherence because of the potential risk of unblinding. However, several pre-exposure prophylaxis trials for HIV-1 prevention among women failed to show effectiveness because of low product adherence. Evaluation of product adherence objectively during a study provides the opportunity for strengthening adherence activities at sites having low adherence. METHODS: During MTN-020/ASPIRE, a phase III, placebo-controlled trial of the dapivirine intravaginal ring, we implemented an adherence monitoring system. Monitoring began in quarter 1 (Q1) 2013 and continued through the conclusion of the trial. Blood plasma was collected quarterly and tested for dapivirine concentrations while maintaining blinding among study team members involved in participant management. Dapivirine concentrations >95 pg/mL, reflecting >8 hours of continuous use, were assessed as signaling product use. Study leadership monitored results on a monthly basis and provided feedback to site investigators. Experiences were shared across sites to motivate staff and counsel participants to strive toward higher adherence levels. RESULTS: An upward trend in adherence was observed (P < 0.0001); the proportion of samples from subjects in the active arm with dapivirine >95 pg/mL increased from 63% in Q1 2013 to 84% by Q1 2015. CONCLUSIONS: Ongoing drug level testing as a marker of adherence in MTN-020/ASPIRE demonstrates the feasibility of real-time adherence monitoring while maintaining study blinding at the level of participants, sites, and study leadership. This approach is novel for large-scale effectiveness studies for HIV-1 prevention.
Authors: Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor Journal: Science Date: 2010-07-19 Impact factor: 47.728
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: Ariane van der Straten; Erica N Browne; Mary Kate Shapley-Quinn; Elizabeth R Brown; Krishnaveni Reddy; Rachel Scheckter; Lydia Soto-Torres; Thesla Palanee-Phillips; Jared M Baeten; Barbara Mensch Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Matthew A Spinelli; David V Glidden; Peter L Anderson; Monica Gandhi; Stephanie Cohen; Eric Vittinghoff; Megan E Coleman; Hyman Scott; Oliver Bacon; Richard Elion; Michael A Kolber; Susan P Buchbinder; Albert Y Liu Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Sharon A Riddler; Jennifer E Balkus; Urvi M Parikh; John W Mellors; Carolyne Akello; Sufia Dadabhai; Felix Mhlanga; Gita Ramjee; Ashley J Mayo; Edward Livant; Amy L Heaps; Colin O'Rourke; Jared M Baeten Journal: Clin Infect Dis Date: 2019-07-18 Impact factor: 9.079
Authors: Ashley J Mayo; Erica N Browne; Elizabeth T Montgomery; Kristine Torjesen; Thesla Palanee-Phillips; Nitesha Jeenarain; Linly Seyama; Kubashni Woeber; Ishana Harkoo; Krishnaveni Reddy; Tchangani Tembo; Prisca Mutero; Thelma Tauya; Miria Chitukuta; Brenda Gati Mirembe; Lydia Soto-Torres; Elizabeth R Brown; Jared M Baeten; Ariane van der Straten Journal: AIDS Behav Date: 2021-03-13
Authors: Marla J Husnik; Elizabeth R Brown; Sufia S Dadabhai; Zakir Gaffoor; Nitesha Jeenarain; Flavia Matovu Kiweewa; Edward Livant; Leila E Mansoor; Brenda Gati Mirembe; Thesla Palanee-Phillips; Devika Singh; Samantha Siva; Lydia Soto-Torres; Ariane van der Straten; Jared M Baeten Journal: AIDS Behav Date: 2021-06-11
Authors: Elizabeth R Brown; Craig W Hendrix; Ariane van der Straten; Flavia M Kiweewa; Nyaradzo M Mgodi; Thesla Palanee-Philips; Mark A Marzinke; Linda-Gail Bekker; Lydia Soto-Torres; Sharon L Hillier; Jared M Baeten Journal: J Int AIDS Soc Date: 2020-11 Impact factor: 5.396